Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib and Temozolomide in Platinum-Sensitive Biliary Tract Cancer
NCT04796454Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pamiparib in biliary tract cancer (BTC), sponsored by European Organisation for Research and Treatment of Cancer. Planned start May 2022; status: withdrawn.
02
Drugs
pamiparib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04796454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796454.